Switch theme
Sign up to access all valuation multiples
Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.
2005
n/a
LTM Revenue $190M
LTM EBITDA $141M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hualan Biological Vaccine has a last 12-month revenue of $190M and a last 12-month EBITDA of $141M.
In the most recent fiscal year, Hualan Biological Vaccine achieved revenue of $155M and an EBITDA of $49.7M.
Hualan Biological Vaccine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hualan Biological Vaccine valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $332M | $155M | XXX | XXX | XXX |
| Gross Profit | $222M | $293M | XXX | XXX | XXX |
| Gross Margin | 67% | 188% | XXX | XXX | XXX |
| EBITDA | $159M | $49.7M | XXX | XXX | XXX |
| EBITDA Margin | 48% | 32% | XXX | XXX | XXX |
| Net Profit | $71.6M | $118M | XXX | XXX | XXX |
| Net Margin | 22% | 76% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hualan Biological Vaccine's stock price is CNY 16 (or $2).
Hualan Biological Vaccine has current market cap of CNY 9.7B (or $1.3B), and EV of CNY 7.9B (or $1.1B).
See Hualan Biological Vaccine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.3B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hualan Biological Vaccine has market cap of $1.3B and EV of $1.1B.
Hualan Biological Vaccine's trades at 5.7x LTM EV/Revenue multiple, and 7.7x LTM EBITDA.
Analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hualan Biological Vaccine and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 21.8x | XXX | XXX | XXX |
| P/E | 47.0x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | 18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHualan Biological Vaccine's NTM/LTM revenue growth is 51%
Hualan Biological Vaccine's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hualan Biological Vaccine's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hualan Biological Vaccine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hualan Biological Vaccine and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -53% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -69% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 83% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 66% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hualan Biological Vaccine acquired XXX companies to date.
Last acquisition by Hualan Biological Vaccine was XXXXXXXX, XXXXX XXXXX XXXXXX . Hualan Biological Vaccine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hualan Biological Vaccine founded? | Hualan Biological Vaccine was founded in 2005. |
| Where is Hualan Biological Vaccine headquartered? | Hualan Biological Vaccine is headquartered in China. |
| Is Hualan Biological Vaccine publicy listed? | Yes, Hualan Biological Vaccine is a public company listed on SHE. |
| What is the stock symbol of Hualan Biological Vaccine? | Hualan Biological Vaccine trades under 301207 ticker. |
| When did Hualan Biological Vaccine go public? | Hualan Biological Vaccine went public in 2022. |
| Who are competitors of Hualan Biological Vaccine? | Similar companies to Hualan Biological Vaccine include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Hualan Biological Vaccine? | Hualan Biological Vaccine's current market cap is $1.3B |
| What is the current revenue of Hualan Biological Vaccine? | Hualan Biological Vaccine's last 12-month revenue is $190M. |
| What is the current EBITDA of Hualan Biological Vaccine? | Hualan Biological Vaccine's last 12-month EBITDA is $141M. |
| What is the current EV/Revenue multiple of Hualan Biological Vaccine? | Current revenue multiple of Hualan Biological Vaccine is 5.7x. |
| What is the current EV/EBITDA multiple of Hualan Biological Vaccine? | Current EBITDA multiple of Hualan Biological Vaccine is 7.7x. |
| What is the current revenue growth of Hualan Biological Vaccine? | Hualan Biological Vaccine revenue growth between 2023 and 2024 was -53%. |
| Is Hualan Biological Vaccine profitable? | Yes, Hualan Biological Vaccine is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
